Angiogenesis, lymphangiogenesis, and melanoma metastasis

The induction of angiogenesis is a critical point in the development of most human tumors – including melanomas. Some of the earliest studies in the field of tumor angiogenesis showed that transplantation of human melanoma fragments into the hamster cheek pouch stimulated blood vessel growth. Since then, numerous studies have demonstrated that human melanomas also induce angiogenesis. The prognostic importance of the degree of melanoma vascularization, however, has remained controversial. Elevated expression of several angiogenic factors, including vascular endothelial growth factor, basic fibroblast growth factor, and interleukin-8, has been detected in primary cutaneous melanomas, and the importance of these mediators in promoting melanoma angiogenesis and metastasis has been confirmed in tumor xenotransplant models. Based upon these findings, several clinical trials of angiogenesis inhibitors have been initiated in human melanoma patients and are currently underway. Recent experimental evidence indicates that tumor-associated lymphangiogenesis also plays an important role in mediating tumor spread to regional lymph nodes. These observations have important implications for prognosis and treatment of human melanomas.

[1]  J. Posey,et al.  A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti alpha v beta 3) antibody in patients with metastatic cancer. , 2001, Cancer biotherapy & radiopharmaceuticals.

[2]  D. Hanahan,et al.  Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.

[3]  S. Asko-Seljavaara,et al.  Prognostic value of tumour vascularity in primary melanoma. , 1999, Melanoma research.

[4]  B. Mian,et al.  Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma. , 2002, The American journal of pathology.

[5]  Jordi Graells,et al.  Angiogenesis and malignant melanoma. Angiogenesis is related to the development of vertical (tumorigenic) growth phase , 1997, Journal of cutaneous pathology.

[6]  H. Wiley,et al.  Expression of CC chemokine receptor-7 and regional lymph node metastasis of B16 murine melanoma. , 2001, Journal of the National Cancer Institute.

[7]  P. Carmeliet,et al.  Angiogenesis in cancer and other diseases , 2000, Nature.

[8]  R K Jain,et al.  Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[9]  N. Ferrara.  Vascular endothelial growth factor: molecular and biological aspects. , 1999, Current topics in microbiology and immunology.

[10]  J. Folkman,et al.  Looking for a good endothelial address. , 2002, Cancer cell.

[11]  M. Herlyn,et al.  Basic fibroblast growth factor induces a transformed phenotype in normal human melanocytes , 1999, Oncogene.

[12]  C. Boshoff,et al.  Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer , 2000, British Journal of Cancer.

[13]  D. Schadendorf,et al.  Expression of interleukin‐8 detected by in situ hybridization correlates with worse prognosis in primary cutaneous melanoma , 1999, The Journal of pathology.

[14]  S. Ramakrishnan,et al.  Inhibition of angiogenesis and tumour growth by VEGF121–toxin conjugate: differential effect on proliferating endothelial cells , 2000, British Journal of Cancer.

[15]  M. Detmar,et al.  Thrombospondin‐2 plays a protective role in multistep carcinogenesis: a novel host anti‐tumor defense mechanism , 2001, The EMBO journal.

[16]  P. Heikkilä,et al.  Enhanced expression of vascular endothelial growth factor in metastatic melanoma. , 1997, British Journal of Cancer.

[17]  M. Detmar.  Molecular regulation of angiogenesis in the skin. , 1996, The Journal of investigative dermatology.

[18]  P. Carmeliet,et al.  Heterogeneous vascular dependence of tumor cell populations. , 2001, The American journal of pathology.

[19]  Thomas Hawighorst,et al.  Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis , 2001, Nature Medicine.

[20]  E. Macher,et al.  Tumor angiogenic activity (TAA) production in vitro and growth in the nude mouse by human malignant melanoma. , 1983, European journal of cancer & clinical oncology.

[21]  R. Halaban,et al.  Suppression of autocrine cell proliferation and tumorigenesis of human melanoma cells and fibroblast growth factor transformed fibroblasts by a kinase-deficient FGF receptor 1: evidence for the involvement of Src-family kinases , 1997, Oncogene.

[22]  D J Ruiter,et al.  Transition of horizontal to vertical growth phase melanoma is accompanied by induction of vascular endothelial growth factor expression and angiogenesis , 1997, Melanoma research.

[23]  T. Mcclanahan,et al.  Involvement of chemokine receptors in breast cancer metastasis , 2001, Nature.

[24]  A. Srivastava,et al.  Neovascularization in human cutaneous melanoma: a quantitative morphological and Doppler ultrasound study. , 1986, European journal of cancer & clinical oncology.

[25]  Michael J Morin,et al.  From oncogene to drug: development of small molecule tyrosine kinase inhibitors as anti-tumor and anti-angiogenic agents , 2000, Oncogene.

[26]  J. Cyster,et al.  A chemokine expressed in lymphoid high endothelial venules promotes the adhesion and chemotaxis of naive T lymphocytes. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[27]  C. Heldin,et al.  Platelet-derived growth factor (PDGF) in oncogenesis: development of a vascular connective tissue stroma in xenotransplanted human melanoma producing PDGF-BB. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[28]  M. Herlyn,et al.  Proliferation of human malignant melanomas is inhibited by antisense oligodeoxynucleotides targeted against basic fibroblast growth factor. , 1989, The EMBO journal.

[29]  Steven A. Stacker,et al.  VEGF-D promotes the metastatic spread of tumor cells via the lymphatics , 2001, Nature Medicine.

[30]  M. Detmar,et al.  The rediscovery of the lymphatic system: old and new insights into the development and biological function of the lymphatic vasculature. , 2002, Genes & development.

[31]  R. Halaban,et al.  Transformation of murine melanocytes by basic fibroblast growth factor cDNA and oncogenes and selective suppression of the transformed phenotype in a reconstituted cutaneous environment , 1989, The Journal of cell biology.

[32]  S. Ugurel,et al.  Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  D. Hicklin,et al.  Active Immunization Against the Vascular Endothelial Growth Factor Receptor flk1 Inhibits Tumor Angiogenesis and Metastasis , 2002, The Journal of experimental medicine.

[34]  L. Akslen,et al.  Importance of vascular phenotype by basic fibroblast growth factor, and influence of the angiogenic factors basic fibroblast growth factor/fibroblast growth factor receptor-1 and ephrin-A1/EphA2 on melanoma progression. , 2002, The American journal of pathology.

[35]  William Arbuthnot Sir Lane,et al.  Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth , 1997, Cell.

[36]  Ericka Stricklin-Parker,et al.  Ann , 2005 .

[37]  K. Alitalo,et al.  Prognostic value of tumour vascularity in metastatic melanoma and association of blood vessel density with vascular endothelial growth factor expression. , 1999, Melanoma research.

[38]  S. Stacker,et al.  Localization of vascular endothelial growth factor‐D in malignant melanoma suggests a role in tumour angiogenesis , 2001, The Journal of pathology.

[39]  K. Kinzler,et al.  Genes expressed in human tumor endothelium. , 2000, Science.

[40]  K. Alitalo,et al.  Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. , 2002, Journal of the National Cancer Institute.

[41]  S. Stacker,et al.  The role of tumor lymphangiogenesis in metastatic spread , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[42]  T. Saida,et al.  What is the most promising strategy for the treatment of metastasizing melanoma? , 2000, Experimental dermatology.

[43]  J. Holaday,et al.  Administration of a liposomal FGF-2 peptide vaccine leads to abrogation of FGF-2-mediated angiogenesis and tumor development. , 2000, Vaccine.

[44]  W. Schmiegel,et al.  Melanoma-associated expression of vascular endothelial growth factor and its receptors FLT-1 and KDR , 1999, Journal of Cancer Research and Clinical Oncology.

[45]  K. Messmer,et al.  Inhibition of the alpha-ν integrins with a cyclic RGD peptide impairs angiogenesis, growth and metastasis of solid tumours in vivo , 2002, British Journal of Cancer.

[46]  Mehdi Nosrati,et al.  Tumor vascularity in the prognostic assessment of primary cutaneous melanoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  G. Westbury,et al.  The vascularity of cutaneous melanoma: a quantitative histological study of lesions 0.85-1.25 mm in thickness. , 1991, British Journal of Cancer.

[48]  M. Dewhirst,et al.  Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[49]  L. Orci,et al.  Vascular endothelial growth factor‐C‐mediated lymphangiogenesis promotes tumour metastasis , 2001, The EMBO journal.

[50]  S. Hirakawa,et al.  The Formation of Lymphatic Vessels and Its Importance in the Setting of Malignancy , 2002, The Journal of experimental medicine.

[51]  M. Detmar,et al.  Thrombospondin-1 selectively inhibits early-stage carcinogenesis and angiogenesis but not tumor lymphangiogenesis and lymphatic metastasis in transgenic mice , 2002, Oncogene.

[52]  S. Tóth,et al.  Autocrine and paracrine regulation by cytokines and growth factors in melanoma. , 2000, Cytokine.

[53]  M. Ueda,et al.  Expression of fibroblast growth factor receptors in naevus-cell naevus and malignant melanoma , 1997, Melanoma research.

[54]  Napoleone Ferrara,et al.  Clinical applications of angiogenic growth factors and their inhibitors , 1999, Nature Medicine.

[55]  M. Detmar,et al.  An essential role for Prox1 in the induction of the lymphatic endothelial cell phenotype , 2002, The EMBO journal.

[56]  M. Skobe,et al.  Concurrent induction of lymphangiogenesis, angiogenesis, and macrophage recruitment by vascular endothelial growth factor-C in melanoma. , 2001, The American journal of pathology.

[57]  P. Lacal,et al.  Human melanoma cells secrete and respond to placenta growth factor and vascular endothelial growth factor. , 2000, The Journal of investigative dermatology.

[58]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.

[59]  H. Antoniades,et al.  Expression of platelet‐derived growth factor (PDGF)‐A, PDGF‐B and the PDGF‐alpha receptor, but not the PDGF‐beta receptor, in human malignant melanoma in vivo , 1996, The British journal of dermatology.

[60]  T. Kurosaki,et al.  Mutant p53 correlates with reduced expression of thrombospondin-1, increased angiogenesis, and metastatic progression in melanoma. , 1998, Cancer detection and prevention.

[61]  R. Halaban,et al.  Human melanoma cells but not normal melanocytes express vascular endothelial growth factor receptors. , 1993, Biochemical and biophysical research communications.

[62]  D. Ferguson,et al.  Mouse LYVE-1 Is an Endocytic Receptor for Hyaluronan in Lymphatic Endothelium* , 2001, The Journal of Biological Chemistry.

[63]  D. Cheresh,et al.  Synergy between an antiangiogenic integrin alphav antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[64]  H. Dvorak,et al.  Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. , 1983, Science.

[65]  J. Wolf,et al.  Melanoma. Tumor angiogenesis and human neoplasia , 1976, Cancer.

[66]  L. Akslen,et al.  Expresson of vascular endothelial growth factor, its receptors (FLT-1, KDR) and TSP-1 related to microvessel density and patient outcome in vertical growth phase melanomas. , 2001, The American journal of pathology.

[67]  P. Meltzer,et al.  Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. , 1999, The American journal of pathology.

[68]  D. Dréau,et al.  Angiogenic and immune parameters during recombinant interferon-alpha2b adjuvant treatment in patients with melanoma. , 2001, Oncology research.

[69]  Lars Holmgren,et al.  Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma , 1994, Cell.

[70]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[71]  D. Kerr,et al.  Melanoma cell lines express VEGF receptor KDR and respond to exogenously added VEGF. , 1995, Biochemical and biophysical research communications.

[72]  Thomas Boehm,et al.  Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance , 1997, Nature.

[73]  C. Dinney,et al.  Inhibition of tumor growth by systemic treatment with thrombospondin‐1 peptide mimetics , 2002, International journal of cancer.

[74]  E. Rofstad,et al.  Hypoxia-associated spontaneous pulmonary metastasis in human melanoma xenografts: involvement of microvascular hot spots induced in hypoxic foci by interleukin 8 , 2002, British Journal of Cancer.

[75]  J. Menell,et al.  Temozolomide plus thalidomide in patients with advanced melanoma: results of a dose-finding trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[76]  J. Folkman,et al.  Tumor angiogenesis: a possible control point in tumor growth. , 1975, Annals of internal medicine.